SERUM SORUBLE CD27 LEVEL DETERMINES CLINICAL OUTCOME IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA IN RITUXIMAB ERA

被引：0
|
作者：
Coto, N.
Tsurumi, H. [1 ]
Kanemura, N. [1 ]
Kasahara, S. [1 ]
Hara, T. [1 ]
Kito, Y. [2 ]
Takami, T. [2 ]
Moriwaki, H. [1 ]
Nakamura, H. [1 ]
机构：
[1] Gifu Univ, Grad Sch Med, Dept Internal Med 1, Gifu, Japan
[2] Gifu Univ, Grad Sch Med, Dept Immunopathol, Gifu, Japan
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2010年 / 95卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0671
引用
收藏
页码：281 / 281
页数：1
相关论文
共 50 条
  • [41] De novo CD5+diffuse large B-cell lymphoma, NOS: clinical characteristics and outcomes in rituximab era
    Hu, Bei
    Nastoupil, Loretta J.
    Loghavi, Sanam
    Westin, Jason R.
    Thakral, Beenu
    Fayad, Luis E.
    Hagemeister, Fredrick
    Neelapu, Sattva
    Samaniego, Felipe
    Lee, Hun J.
    Wang, Michael L.
    Fanale, Michelle
    Fowler, Nathan
    Oki, Yasuhiro
    LEUKEMIA & LYMPHOMA, 2020, 61 (02) : 328 - 336
  • [42] Late relapse in patients with diffuse large B-cell lymphoma: impact of rituximab on their incidence and outcome
    Vannata, Barbara
    Conconi, Annarita
    Winkler, Jonas
    Cascione, Luciano
    Casaluci, Gloria Margiotta
    Nassi, Luca
    Moia, Riccardo
    Pirosa, Maria Cristina
    Moccia, Alden A.
    Stathis, Anastasios
    Rossi, Davide
    Gaidano, Gianluca
    Zucca, Emanuele
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 187 (04) : 478 - 487
  • [43] Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era
    Bobillo, Sabela
    Joffe, Erel
    Lavery, Jessica A.
    Sermer, David
    Ghione, Paola
    Noy, Ariela
    Caron, Philip C.
    Hamilton, Audrey
    Hamlin, Paul A.
    Horwitz, Steven M.
    Kumar, Anita
    Matasar, Matthew J.
    Moskowitz, Alison
    Owens, Colette N.
    Palomba, M. Lia
    Batlevi, Connie L.
    Straus, David
    von Keudell, Gottfried
    Zelenetz, Andrew D.
    Yahalom, Joachim
    Dogan, Ahmet
    Seshan, Venkatraman E.
    Younes, Anas
    BLOOD, 2021, 137 (01) : 39 - 48
  • [44] Rituximab and CHOP for elderly patients with diffuse large B-cell lymphoma
    Carol S. Portlock
    Current Oncology Reports, 2003, 5 (5) : 357 - 357
  • [45] Rituximab and chemotherapy in diffuse large B-cell lymphoma
    Sonet, Anne
    Bosly, Andre
    EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (06) : 719 - 726
  • [46] Clinical characteristics and prognosis of patients with co-existing follicular lymphoma and diffuse large B-cell lymphoma components in rituximab era
    Chen, Yi
    Luo, Luting
    Chen, Lushan
    Zheng, Xiaoyun
    Yang, Xiaozhu
    Zheng, Zhihong
    Zheng, Jing
    Liu, Tingbo
    Yang, Ting
    Hu, Jianda
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (06) : 2311 - 2318
  • [47] Clinical characteristics and prognosis of patients with co-existing follicular lymphoma and diffuse large B-cell lymphoma components in rituximab era
    Yi Chen
    Luting Luo
    Lushan Chen
    Xiaoyun Zheng
    Xiaozhu Yang
    Zhihong Zheng
    Jing Zheng
    Tingbo Liu
    Ting Yang
    Jianda Hu
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 2311 - 2318
  • [48] Outcome of diffuse large B cell lymphoma in the VA system: The rituximab era.
    Komrokji, Rami S.
    Maraboyina, Sanjay
    Haddad, Rami Y.
    Nahleh, Zeina A.
    Safa, Malek M.
    BLOOD, 2006, 108 (11) : 265B - 265B
  • [49] Role of consolidative radiation therapy for patients with mediastinal diffuse large B-cell lymphoma in the rituximab era
    Sert, Fatma
    Kamer, Serra
    Saydam, Guray
    Anacak, Yavuz
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2018, 14 (06) : 1397 - 1402
  • [50] The rationale and role of radiation therapy in the treatment of patients with diffuse large B-cell lymphoma in the Rituximab era
    Wirth, Andrew
    LEUKEMIA & LYMPHOMA, 2007, 48 (11) : 2121 - 2136
12345